Tag Archives: Alzheimer’s Prevention Initiative Study

Summary of Recent Progress in Alzheimer’s Disease Prevention Trials (CTAD / JPAD)

Posted on October 1, 2018 by Dementia and Elderly Care News

Summary The following article summarises a round-up of present understanding and developments reflected in current and planned prevention trials, as discussed at a EU / US / Clinical Trials in Alzheimer’s Disease (CTAD) Task Force meeting, as of December 2016-7. … Continue reading →

Developments in Dementia Research: From the Horses’ Mouths (NHS England / NIHR)

Posted on August 25, 2016 by Dementia and Elderly Care News

Summary Professor Alistair Burns (NHS England’s National Clinical Director for Dementia and Older Peoples’ Mental Health), and Professor Martin Rossor (NIHR National Director for Dementia Research), discuss current issues and new approaches in dementia research, touching briefly upon some of … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Models of Dementia Care, National, NHS England, NIHR, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged 100000 Genomes Project, A4 Study, Alistair Burns: Honorary Consultant Old Age Psychiatrist in the Manchester Mental Health and Social Care Trust (MMHSCT), Alistair Burns: NHS England’s National Clinical Director for Older People’s Mental Health, Alistair Burns: Professor of Old Age Psychiatry at University of Manchester, Alzheimer's Prevention Initiative, Alzheimer’s Disease Biomarkers, Alzheimer’s Prevention Initiative Study, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4 Study), APP and Presenilin, Asymptomatic Alzheimer’s Disease, Banner Alzheimer's Institute, Biomarkers, Chance Genetic Mutations, Colombia, Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, DIAN-TU Study, DIAN-TU Trial, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Genentech, Genomics, Genomics England, Genomics in the NHS, Genomics-Based Medicine, Global Outlook, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Medellin (Colombia), Monoclonal Antibodies, MRC Neurochemical Pharmacology Unit, Mutational Signatures, National Clinical Director for Dementia, National Institute for Health Research (NIHR), National Institutes of Health (NIH), National Institutes of Health (US), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, NIHR Clinical Research Network, NIHR Dementia Translational Research Collaboration, NIHR National Director for Dementia Research, NIHR Translational Research Collaboration, Overcoming Barriers, Participation in Research, Participation in Research Studies, Preclinical Alzheimer's Disease, Presenilin, Prodromal Alzheimer's Disease, Professor Alistair Burns, Professor Martin Rossor: Director of the NIHR Queen Square Dementia Biomedical Research Unit, Professor Martin Rossor: Former Director of the NIHR Dementia and Neurodegenerative Disease Research Network (DeNDRoN), Professor Martin Rossor: Former President of the Association of British Neurologists (2011-2013), Professor Martin Rossor: Honorary Consultant Neurologist at National Hospital for Neurology and Neurosurgery, Professor Martin Rossor: National Hospital (Queen Square), Professor Martin Rossor: NIHR National Director for Dementia Research, Professor Martin Rossor: UCL Institute of Neurology, Promisary Science, Reducing Downstream Effects of Disease, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Research Promotion, Sharing Knowledge and Information, Slowing Progression of Disease (Stabilisation), Solanezumab (Sola or Solab), Solanezumab: Humanised Monoclonal Antibody, Therapeutic Nihilism (Avoiding), Translational Research, UK Genomes Project: Genomics England, University of Southern California’s Alzheimer’s Therapeutic Research Institute, Washington University School of Medicine | Leave a comment

Tag Archives: Alzheimer’s Prevention Initiative Study

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites